Company profile: Alvine Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of biopharmaceutical therapeutics for autoimmune and gastrointestinal diseases; developing and commercializing treatments including ALV003, a combination protease engineered to digest gluten for patients with celiac disease.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Alvine Pharmaceuticals
Corbus Pharmaceuticals
HQ: United States
Website
- Description: Provider of clinical-stage therapeutics targeting inflammatory and fibrotic diseases, with programs in oncology and obesity. Pipeline includes CRB-701, a next-generation Nectin-4-targeting ADC in trials for advanced solid tumors; CRB-601, an anti-integrin monoclonal antibody blocking TGFβ activation on cancer cells; and CRB-913, a peripherally restricted CB1 inverse agonist for obesity with IND planned.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Corbus Pharmaceuticals company profile →
Cell IDx
HQ: United States
Website
- Description: Provider of multiplexed cellular immunodiagnostics solutions, developing highly sensitive and specific reagents for research and clinical immunohistochemistry, and offering UltraPlex technology for multiplex chromogenic and fluorescent tissue staining suitable for high-throughput biomarker tissue profiling.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cell IDx company profile →
ProtaGene
HQ: Germany
Website
- Description: Provider of precision medicine solutions supporting drug development, treatment strategies, and patient management, with expertise in immuno-profiling and discovery of novel autoantibody signatures for autoimmune disease and immuno-oncology, leveraging SeroTag® technology to identify biomarkers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ProtaGene company profile →
ADMA Biologics
HQ: United States
Website
- Description: Provider of plasma-based biologics, including ASCENIV IVIG for primary immunodeficiency disease (PIDD) and other immune-compromised conditions; BIVIGAM IVIG for primary humoral immunodeficiency (PI); Nabi-HB hyperimmune globulin to prevent hepatitis B infection following exposure; and ADMA BioCenters, a network of plasma collection centers supplying high-quality plasma for immunoglobulin manufacturing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ADMA Biologics company profile →
DBV Technologies
HQ: France
Website
- Description: Provider of investigational epicutaneous immunotherapy products for food allergies and other immunological disorders via the Viaskin technology platform, including Viaskin Peanut, a patch delivering small amounts of peanut protein to the skin. Also developing Viaskin-based approaches for other food allergies, an investigational diagnostic for non-IgE-mediated milk allergy, and non-invasive vaccine delivery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full DBV Technologies company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Alvine Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Alvine Pharmaceuticals
2.2 - Growth funds investing in similar companies to Alvine Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Alvine Pharmaceuticals
4.2 - Public trading comparable groups for Alvine Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →